At ReadCoor, we envision swifter scientific discoveries, disease diagnosis and drug development from sequencing reads enhanced by panomic spatial data.
Current next generation sequencing methods require the structural breakdown of samples to identify molecular targets of interest. Grinding samples into fragments is the conventional method scientists use to identify the nucleic sequences of a sample. Although this process provides researchers with a list of sequences, the corresponding spatial data associated with the sequences is lost.
Spatial sequencing methods focus on the preservation of locational data to identify molecule coordinates and provide insight into the relational nature of molecules and cells. By identifying the three-dimensional coordinates of molecular targets, spatial sequencing provides a more robust understanding of the dynamic cellular and molecular forces that contribute to health, disease and cell development. This level of detail can help scientists begin to advance our understanding of the neighboring influences of co-cultured cancer cells or the nexus of cancerous and healthy tissue, among many other scientific and clinical insights.
Current spatial sequencing methods require a clearly identified target, and are limited in their sequencing capacity to a single target. Panomic spatial sequencing offers the ability to sequence across a molecular range, from genomics to metabolomics, resulting in a truly panomic sequencing experience and greater scientific insight.
ReadCoor’s spatial sequencing platform, Fluorescent in situ Sequencing (FISSEQ), provides further scientific insight in the form of panomic readouts that capture cell morphology. Reads from FISSEQ are presented in a 3D image of molecular targets in tissue or cell samples. The high level of detailed cellular and molecular information captured through the FISSEQ platform provides researchers more data-enriched reads contributing to accelerated discoveries, diagnosis and treatment.
In February of 2014, FISSEQ was first published in the journal Science.¹ Using 30-base reads from 8742 genes in situ, we examined RNA expression and localization in human primary fibroblasts with a simulated wound-healing assay, detecting 12 differentially regulated genes. The following year the FISSEQ method was published in Nature Protocols, extending access to researchers worldwide.² Following the Science publication, a team of scientists and leaders from the Wyss Institute for Biologically Inspired Engineering at Harvard University came together to transform FISSEQ into the panomic platform that it is today. After two years of careful development and completion of a financing round, our founding team spun out of the Wyss Institute and launched ReadCoor.
Shortly following the spinout, our team secured its first partnership through a grant from the Bill and Melinda Gates Foundation. The partnership was the first of four partnerships we secured over the next year. Other partners include the Intelligence Advanced Research Projects Activity (IARPA), WAVE Life Sciences and The Joint Pathology Center. In April of 2017, Nature Biotechnology named ReadCoor a leading spinout.
Our team continues to advance the spatial sequencing frontier by increasing the number of molecules sequenced per cell, optimizing sequencing library construction, and applying new microscopy and sequencing modalities.
Join Our Select Release Program!
“Our Select Release Program (SRP) serves as the foundation for researchers to develop new therapeutics and treatments to ultimately improve patient care.”
~Richard Terry, CEO, CTO, and Founder, ReadCoor
Join our Select Release Program to gain access to our fully integrated true multi-omic spatial sequencing platform. It is now available for use with initial applications focusing on immuno-oncology, neuroscience, and infectious disease, as well as a custom offering.
The RC2 platform is for research use only. Not for use in diagnostic procedures.